Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance, second edition. Geneva: World Health Organization; 2023 (https://www.who.int/publications/i/item/9789240082410).
WHO consolidated guidelines on tuberculosis. Module 3: Diagnosis – rapid diagnostics for tuberculosis detection, 2021 update. Geneva: World Health Organization; 2021 (https://www.who.int/publications/i/item/9789240029415).
WHO operational handbook on tuberculosis. Module 3: Diagnosis – rapid diagnostics for tuberculosis detection, 2021 update. Geneva: World Health Organization; 2021 (https://www.who.int/publications/i/item/9789240030589).
World Health Organization G. TB Knowledge Sharing – Training Catalogue [online training course] [website]. 2021 (https://tbksp.org/en/node/1722).
WHO consolidated guidelines on tuberculosis. Module 3: Diagnosis – rapid diagnostics for tuberculosis detection, third edition. Geneva: World Health Organization; 2024 (https://iris.who.int/handle/10665/376221).
Definitions and reporting framework for tuberculosis – 2013 revision (updated December 2014 and January 2020) (WHO/HTM/TB/2013.2). Geneva: World Health Organization; 2020 (https://www.who.int/publications/i/item/9789241505345).
Manual for selection of molecular WHO-recommended rapid diagnostic tests for detection of tuberculosis and drug-resistant tuberculosis. Geneva: World Health Organization; 2022 (https://www.who.int/publications/i/item/9789240042575).
Sengstake S, Rigouts L. A multicenter evaluation of the Genoscholar PZA-TB II line probe assay to detect pyrazinamide resistance in Mycobacterium tuberculosis isolates: study report. Antwerp.: Institute of Tropical Medicine; 2020.
Beviere M, Reissier S, Penven M, Dejoies L, Guerin F, Cattoir V, Piau C. The Role of Next-Generation Sequencing (NGS) in the Management of Tuberculosis: Practical Review for Implementation in Routine. Pathogens. 2023;12(8).
Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. Geneva: World Health Organization; 2018 (https://www.who.int/publications/i/item/WHO-CDS-TB-2018.5).
HIV Reagent Program [website]. National Institutes of Health HIV Reagent Program; 2023 (https://www.beiresources.org/).
Technical report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins (rifampicin, rifabutin and rifapentine). Geneva: World Health Organization; 2021 (https://www.who.int/publications/i/item/9789240017283).
World Health Organization, Foundation for Innovative New Diagnostics. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide (WHO/CDS/TB/2018.19. Geneva: World Health Organization; 2018 (https://www.who.int/publications/i/item/WHO-CDS-TB-2018.19).
The use of next-generation sequencing for the surveillance of drug-resistant tuberculosis: an implementation manual. Geneva: World Health Organization; 2023 (https://www.who.int/publications/i/item/9789240078079).
ISO 15189: 2022 Medical laboratories – requirements for quality and competence. Geneva: International Organization for Standardization; 2022 (https://www.iso.org/standard/76677.html).
Gargis AS, Kalman L, Berry MW, Bick DP, Dimmock DP, Hambuch T et al. Assuring the quality of nextgeneration sequencing in clinical laboratory practice. Nat Biotechnol. 2012;30(11):1033–6 (https://doi.org/10.1038/nbt.2403).
Tornheim JA, Starks AM, Rodwell TC, Gardy JL, Walker TM, Cirillo DM et al. Building the framework for standardized clinical laboratory reporting of next-generation sequencing data for resistance-associated mutations in Mycobacterium tuberculosis complex. Clin Infect Dis. 2019;69(9):1631–3 (https://doi.org/10.1093/cid/ciz219).
Van Deun A, Aung KJ, Bola V, Lebeke R, Hossain MA, de Rijk WB et al. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol. 2013;51(8):2633–40 (https://doi.org/10.1128/JCM.00553-13).
Berhanu RH, Schnippel K, Kularatne R, Firnhaber C, Jacobson KR, Horsburgh CR, Lippincott CK. Discordant rifampicin susceptibility results are associated with Xpert((R)) MTB/RIF probe B and probe binding delay. Int J Tuberc Lung Dis. 2019;23(3):358–62 (https://doi.org/10.5588/ijtld.16.0837).
Beylis N, Ghebrekristos Y, Nicol M. Management of false-positive rifampicin resistant Xpert MTB/ RIF. Lancet Microbe. 2020;1(6):e238 (https://doi.org/10.1016/S2666-5247(20)30123-3).
Ngabonziza JCS, Decroo T, Migambi P, Habimana YM, Van Deun A, Meehan CJ et al. Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective observational study in Rwanda. Lancet Microbe. 2020;1(2):e74-e83 (https://doi.org/10.1016/s2666-5247(20)30007-0).
Chakravorty S, Simmons AM, Rowneki M, Parmar H, Cao Y, Ryan J et al. The New Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing. mBio. 2017;8(4) (https://doi.org/10.1128/mbio.00812-17).
Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis. 2018;18(1):76–84 (https://doi.org/10.1016/S1473-3099(17)30691-6)
Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014;2014(1):CD009593 (https://doi.org/10.1002/14651858.CD009593.pub3).
Cao Y, Parmar H, Gaur RL, Lieu D, Raghunath S, Via N et al. Xpert MTB/XDR: A 10-color reflex assay suitable for point of care settings to detect isoniazid-, fluoroquinolone-, and second-line-injectable-drug resistance directly from Mycobacterium tuberculosis-positive sputum. J Clin Microbiol. 2021;59(3) (https://doi.org/10.1128/JCM.02314-20).
Sanchez-Padilla E, Merker M, Beckert P, Jochims F, Dlamini T, Kahn P et al. Detection of drug-resistant tuberculosis by Xpert MTB/RIF in Swaziland. N Engl J Med. 2015;372(12):1181–2 (https://doi.org/10.1056/NEJMc1413930).
Ismail NA, McCarthy K, Conradie F, Stevens W, Ndjeka N. Multidrug-resistant tuberculosis outbreak in South Africa. Lancet Infect Dis. 2019;19(2):134–5 (https://doi.org/10.1016/S1473-3099(18)30715-1).
Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV, 2019 Update. Geneva: Global Laboratory Initiative; 2019 (https://www.who.int/publications/i/item/9789241550604).
Ismail NA, Aono A, Borroni E, Cirillo DM, Desmaretz C, Hasan R et al. A multimethod, multicountry evaluation of breakpoints for bedaquiline resistance determination. Antimicrob Agents Chemother. 2020;64(9) (https://doi.org/10.1128/AAC.00479-20).
Dean AS, Zignol M, Cabibbe AM, Falzon D, Glaziou P, Cirillo DM et al. Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: a multicountry analysis of cross-sectional data. PLoS Med. 2020;17(1):e1003008 (https://doi.org/10.1371/journal.pmed.1003008).